Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Needed: new and better tools to combat latent tuberculosis infection.

× No keyword cloud information.

21 in total

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors: Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal: Am J Respir Crit Care Med Date: 2003-02-15 Impact factor: 21.405

2. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.

Authors: F Gordin; R E Chaisson; J P Matts; C Miller; M de Lourdes Garcia; R Hafner; J L Valdespino; J Coberly; M Schechter; A J Klukowicz; M A Barry; R J O'Brien
Journal: JAMA Date: 2000-03-15 Impact factor: 56.272

3. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Authors: Robert M Jasmer; Jussi J Saukkonen; Henry M Blumberg; Charles L Daley; John Bernardo; Eric Vittinghoff; Mark D King; L Masae Kawamura; Philip C Hopewell
Journal: Ann Intern Med Date: 2002-10-15 Impact factor: 25.391

4. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors:
Journal: MMWR Recomm Rep Date: 2000-06-09

5. Rifampin preventive therapy for tuberculosis in Boston's homeless.

Authors: A Polesky; H W Farber; D J Gottlieb; H Park; S Levinson; J J O'Connell; B McInnis; R L Nieves; J Bernardo
Journal: Am J Respir Crit Care Med Date: 1996-11 Impact factor: 21.405

6. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients.

Authors: R B Byrd; B R Horn; D A Solomon; G A Griggs
Journal: JAMA Date: 1979-03-23 Impact factor: 56.272

7. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Authors: D E Kopanoff; D E Snider; G J Caras
Journal: Am Rev Respir Dis Date: 1978-06

8. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.

Authors:
Journal: Am Rev Respir Dis Date: 1992-01

9. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Authors: Dick Menzies; Richard Long; Anete Trajman; Marie-Josée Dion; Jae Yang; Hamdan Al Jahdali; Ziad Memish; Kamran Khan; Michael Gardam; Vernon Hoeppner; Andrea Benedetti; Kevin Schwartzman
Journal: Ann Intern Med Date: 2008-11-18 Impact factor: 25.391

10. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

Authors:
Journal: MMWR Morb Mortal Wkly Rep Date: 2003-08-08 Impact factor: 17.586

1 in total

Review 1. Is the large simple trial design used for comparative, post-approval safety research? A review of a clinical trials registry and the published literature.

Authors: Robert F Reynolds; Joanna A Lem; Nicolle M Gatto; Sybil M Eng
Journal: Drug Saf Date: 2011-10-01 Impact factor: 5.606

1 in total